Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenue:
Product sales	$ 1,292,689	$ 1,287,422	$ 2,586,177	$ 3,962,987
Royalties	306,376	744,292	1,225,602	2,429,159
Licensing revenue	679,962	312,690	1,947,813	938,070
Development fees and other	722,849	235,054	1,201,472	507,611
Tarsa revenue	426,807	276,931	1,062,480	579,377
[Revenues]	3,428,683	2,856,389	8,023,544	8,417,204
Operating expenses:
Research and development	2,245,000	1,589,136	6,764,287	4,954,572
Cost of goods sold	493,415	814,958	1,028,955	1,890,267
General and administrative	2,121,859	1,512,389	6,416,774	5,174,104
Unallocated facility expenses	883,617	773,994	2,482,790	2,338,574
Inventory reserve				576,021
Loss on sale of patents	824,241		824,241
Severance and other related expense			349,980	1,120,000
[OperatingExpenses]	6,568,132	4,690,477	17,867,027	16,053,538
Operating loss	(3,139,449)	(1,834,088)	(9,843,483)	(7,636,334)
Loss on change in fair value of embedded conversion feature				(8,125,000)
Debt issuance cost				(2,007,534)
Interest and other income	11,052	31,551	62,106	51,123
Interest expense	(2,861,773)	(2,621,071)	(8,395,849)	(6,739,557)
(Loss) gain from investment in former China joint venture		40,051	(1,375,926)	123,881
Loss from investment in Tarsa	(1,301,143)		(2,819,143)
Loss before income taxes	(7,291,313)	(4,383,557)	(22,372,295)	(24,333,421)
Income tax benefit from sale of state tax benefit				359,357
Net loss	$ (7,291,313)	$ (4,383,557)	$ (22,372,295)	$ (23,974,064)
Net loss per share (in Dollars per share)	$ (0.08)	$ (0.05)	$ (0.24)	$ (0.26)
basic and diluted (in Shares)	92,910,238	92,085,584	92,636,692	91,895,038